Amgen Inc. is a biotechnology company. It discovers, develops, manufactures and delivers medicines for the toughest diseases. It focuses on areas of high unmet medical need and leverages its expertise to strive for solutions that improve people’s lives. It operates in the human therapeutics segment. Its marketed products portfolio includes EPOGEN (epoetin alfa); Aranesp (darbepoetin alfa); Parsabiv (etelcalcetide); Neulasta (pegfilgrastim); KANJINTI (trastuzumab-anns); Otezla; BLINCYTO (blinatumomab); ACTIMMUNE (interferon gamma-1b); Neulasta (pegfilgrastim); Sensipar/Mimpara (cinacalcet); Prolia (denosumab); ENBREL; QUINSAIR (levofloxacin); Repatha (evolocumab) and others. It markets ENBREL, a tumor necrosis factor blocker, in the United States and Canada. It markets Otezla, a small molecule that inhibits phosphodiesterase 4, in many countries around the world. It markets Repatha, a proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor, in many countries around the world.
Ticker SymbolAMGN
Company nameAmgen Inc
IPO dateJun 17, 1983
CEOBradway (Robert A)
Number of employees28000
Security typeOrdinary Share
Fiscal year-endJun 17
AddressOne Amgen Center Drive
CityTHOUSAND OAKS
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code91320-1799
Phone18054471000
Websitehttps://www.amgen.com/
Ticker SymbolAMGN
IPO dateJun 17, 1983
CEOBradway (Robert A)